Based on a patented, proprietary algorithm, PD2i Cardiac Analyzer from Vicor Technologies, Inc. (Boca Raton, FL) is promoted by the company as a device that can stratify patients’ risk to die from Sudden Cardiac Death (SCD) within a six month time frame. Moreover, the company believes that its device, which collects all the data within a twenty minute test, that can be administered in a cardiologist’s office, is “superior to all other devices in predicting SCD, with greater than 95% sensitivity and 81% specificity.”
PD2 is already undergoing a large-scale clinical trial, called VITAL, to evaluate its ability to predict the risk of ventricular tachyarrhythmic events. Now the US Army is jumping on the wagon to see if the device is useful for combat triage:
President and CEO, David H. Fater said, “We are very excited about the opportunity to cooperate with the U.S. Army on the Prediction of Injury Severity and Outcome in the Critically Ill Using the Point Correlation Dimension Algorithm. The USAISR is exploring ways to assess the severity of injury, and probability of survival, of critically injured combat casualties and critically ill civilian patients. The intention is for the medical personnel at USAISR, in conjunction with our personnel, to test Vicor’s PD2i algorithm in several diverse cohorts of animal data as well as in human trauma, ICU patients and combat casualties. It is our mutual expectation that deterioration in status due to trauma and/or hemorrhage will lead to dimensional reductions reflected by the PD2i.”
Mr. Fater added, “This collaborative effort is envisioned to lead to development of new comprehensive decision support tools and/or devices that may incorporate the PDI2 algorithm alone or in association with other metrics currently under investigation at USAISR with the aim to monitor, assess status and predict outcome in critically injured humans.”
Product page: PD2i Cardiac Analyzer …
Press release: Vicor Technologies Announces Collaboration Agreement With The U. S. Army For Use Of PD2i Cardiac Analyzer
US Patent: PD2i electrophysiological analyzer
Clinical trial information: The Ability Of The PD2i Cardiac Analyzer To Predict Risk Of Ventricular Tachyarrhythmic Events (VITAL)